摘要
目的探究对终末期肾性维持性血液透析高磷血症的患者采用碳酸司维拉姆进行治疗的临床效果。方法随机选取在我院接受治疗的维持性血液透析患者24例,服用碳酸司维拉姆进行治疗,每2周进行1次血清钙磷值的测定工作,并以此为依据进行药物剂量的增减,以16周为1个疗程,观察和记录患者治疗前后的血钙、血磷,以及钙磷乘积并全段甲状旁腺激素(iPTH)等指标的变化情况。结果治疗以后患者的血磷以及钙磷乘积较治疗前降低,差异有统计学意义(P<0.05),而血钙以及iPTH基本无变化(P>0.05)。结论采用碳酸司维拉姆对维持性血液透析患者进行治疗能够有效地降低血磷及钙磷乘积。
Objective To explore the clinical effect of the treatment of hyperphosphatemia in patients with end-stage renal maintenance hemodialysis with Rahm. Methods 24 cases of hemodialysis patients were selected in our hospital, taking our carbonate dimensional Rahm treatment, every 2 weeks for 1 determination of serum calcium and phosphorus values, and as a basis for drug dose or 16 weeks for 1 courses, observe and record the patients before and after treatment of blood calcium, blood phosphorus and calcium phosphorus product, intact parathyroid hormone （iPTH） and other indicators of changes. Results After the treatment of serum phosphorus and calcium phosphorus product were lower than before treatment, the difference was statistically significant （P〈0.05）, but no change in the level of serum calcium and iPTH （P〉0.05）. Conclusion The treatment of maintenance hemodialysis patients with Rahm can effectively reduce the blood phosphorus and calcium phosphorus product.
出处
《中国继续医学教育》
2017年第5期162-163,共2页
China Continuing Medical Education
